iToBoS landed in Guadalupe for Nano in Bio 2024

Guadeloupe, 14-20/04/2024

iToBoS landed in Guadeloupe, French Caribbean, in the Nano in Bio 2024 International Conference, from April 14th to 20th, with a study conducted by the University of Trieste in collaboration with Elettra Sincrotone Trieste and the IkerBasque Foundation for Science, Vitoria-Gasteiz, Spain.

The talk presented by a PhD student of the University of Trieste at the Congress dealt with the set-up of a drug delivery system to treat advanced melanoma by utilizing bioengineered lipid nanoparticles (LNPs) to encapsulate a deubiquitinating enzyme inhibitor (DUBs), known as 2c, and synthesized in the chemical laboratories at the University of Trieste [1]. DUBs are a heterogeneous family of isopeptidases involved in proteome homeostasis and can also modulate the activity of proteins involved in DNA repair [2]. Moreover, studies suggested that dysregulation of some of them can lead to cancer proliferation. For this reason, DUBs can be considered as targets for the design and development of novel cancer drug treatments.

In this preliminary study, 2c was administered to A375 melanoma cell lines as a free drug and encapsulated in LNPs. The results support an innovative delivery system for the potential treatment of advanced melanoma. The advantage of using LNPs for drug delivery purposes instead of a free drug or other nanomaterials is the possibility of increasing local drug concentration directly in specific regions to avoid systematic side effects (that are present in normal chemotherapy) and to have a more controlled release.


  1. Cersosimo, A. Sgorbissa, C. Foti, S. Drioli, R. Angelica, A. Tomasella, R. Picco, M.S. Semrau, P. Storici, F. Benedetti, F. Berti, C. Brancolini, J. Med. Chem. 58 (2015) 1691–1704.

  2. [5] T.T. Huang, A.D. D’Andrea, Nature Reviews Molecular Cell Biology 7 (2006) 323–334.